Cognitive remediation for breast cancer survivors with mild cognitive deficits
EvalUation of REmediation Programs for Patients Suffering From Mild Cognitive Deficits After CAncer
This study tests a program to help breast cancer survivors improve their memory and thinking skills after treatment to see if it can make their lives better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Lyon and 1 other locations) |
| Trial ID | NCT04808674 on ClinicalTrials.gov |
What this trial studies
This study focuses on addressing cognitive impairments experienced by breast cancer survivors, specifically targeting issues such as memory, attention, and executive function that can arise after treatment. Participants will undergo a cognitive remediation program designed to improve their cognitive abilities and overall quality of life. The study aims to establish a standard of care for patients suffering from cancer-related cognitive impairment (CRCI), which affects a significant portion of breast cancer survivors. By providing targeted interventions, the study seeks to enhance the patients' ability to reintegrate socially and professionally after their cancer treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are breast cancer survivors who have completed treatment and are experiencing cognitive difficulties.
Not a fit: Patients currently undergoing treatment for breast cancer or those with other active cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the cognitive function and quality of life for breast cancer survivors experiencing cognitive deficits.
How similar studies have performed: While there is growing interest in cognitive remediation for cancer survivors, this specific approach for breast cancer patients with CRCI is relatively novel and has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Treated in the past for breast cancer with chemotherapy, surgery, and / or radiotherapy, * Admitted as a day patient at the Henry Gabrielle Hospital or the Pontchaillou CHU Hospital during the study, * Given free, informed consent in writing after being informed orally and in writing of the how the study will proceed. Exclusion Criteria: * Presence of another active cancer, * Ongoing chemotherapy and/or radiotherapy treatment, * Active progression of breast cancer, * History of neurological or psychiatric conditions, * Major disturbances in comprehension that prevent them giving free, informed consent, * Pregnant, parturient or breastfeeding women, * Person under a legal protection measure such as guardianship or curatorship, * People not affiliated to a social security scheme (French Social Security) or beneficiaries of a similar scheme.
Where this trial is running
Lyon and 1 other locations
- Hospices Civils de Lyon - Groupement hospitalier sud - Hôpital Henry Gabrielle - Service de médecine physique et de réadaptation — Lyon, France (Recruiting)
- Hôpital Pontchaillou - Service de Médecine Physique et de Réadaptation — Rennes, France (Recruiting)
Study contacts
- Principal investigator: Sophie JACQUIN-COURTOIS, PhD — Service de médecine physique et de réadaptation, HCL,
- Study coordinator: Sophie JACQUIN-COURTOIS, PhD
- Email: sophie.courtois@chu-lyon.fr
- Phone: 04.78.86.50.64
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.